Search | Clinical Trials Finder

Conditions: Burn
Interventions: Vitamin and Mineral supplementation; Dietary Supplement
Lead sponsor: Southern Illinois University; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Postherpetic Neuralgia
Interventions: lidocaine and tetracaine cream 7%/7%, Placebo; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Lexington, Kentucky • High Point, North Carolina • Winston-Salem, North Carolina + 3 more

Conditions: Cervical Cancer, Precancerous Condition
Interventions: Eflornithine, Placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms, Unknown Primary
Interventions: Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 31
States / cities: Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 28 more

Conditions: AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions: Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5); Device
Lead sponsor: Notal Vision Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cancer
Interventions: gemcitabine hydrochloride, tacedinaline; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 11
States / cities: Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 8 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions: Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes; Drug · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 4
States / cities: Salt Lake City, Utah • Seattle, Washington

Conditions: Multiple Myeloma, Relapse Multiple Myeloma
Interventions: Descartes-25; Drug
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Shreveport, Louisiana • Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: pomegranate juice; Dietary Supplement
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Elderly; Renal Insufficiency
Interventions: Computer-Assisted Decision Support; Procedure
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Fluid Balance, Input and Output, Inflammatory Mediators, Acute Kidney Injury, Mortality
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: CORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANT
Interventions: Experimental; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 88 Years to 88 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: HIV Infections
Interventions: Zidovudine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: B-Cell Lymphoma
Interventions: Clofarabine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
Interventions: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Multiple Myeloma, Stem Cell Transplant Complications
Interventions: PARE, Waitlist Control Group; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Diarrhea
Interventions: OPT-80; Drug
Lead sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New Hope, Pennsylvania

Conditions: Mild to Moderate Persistent Asthma
Interventions: Activation Energy Serum; Dietary Supplement
Lead sponsor: California Allergy and Asthma Medical Group, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: Closed-loop auditory stimulation, Sham auditory stimulation; Device
Lead sponsor: Fabio Ferrarelli; Other
Eligibility: 18 Years to 40 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ornithine Transcarbamylase Deficiency
Interventions: No Intervention; Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Type I Diabetes, Pediatrics, Food Insecurity
Interventions: Community Servings, PedsQL Survey, Nutrition Counseling, SDOH Survey; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pain, Post Operative, Quality of Life
Interventions: Ibuprofen 600 mg, Placebo, Acetaminophen; Drug
Lead sponsor: Marquette University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Age - Related Macular Degeneration (AMD)
Interventions: Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 46 more

Search by objective public record fields.

Burn Micronutrient Repletion Pilot Study

Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer

Using Informatics to Enhance Care of Older Emergency Department Patients

Fluid Balance and Clinical Outcomes

SINGLE PATIENT EXPANDED ACCESS OF A PROSPECTIVE, MULTICENTER CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND PROBABLE BENEFIT OF THE KERAKLEAR NON-PENETRATING KERATOPROSTHESIS IN SUBJECTS WITH CORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANT

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.

Restoring Spindle and Thalamocortical Efficiency in Early-Course Schizophrenia Patients Using Auditory Stimulation

Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency

Food is Medicine in Pediatric Patients With Diabetes

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)